Role of Race in Nutritional Approach in Men on ADT

Recruiting now · Not applicable

Conditions studied: Prostate Cancer Metastatic Disease

In brief

There is a well-documented association between androgen deprivation therapy (ADT) and cardiovascular morbidity. A majority of men on ADT gain weight contributing to an increase in cardiovascular risk factors (CVRFs) and cardiovascular morbidity. Dietary intervention combined with exercise have shown success in reducing weight/fat mass and improving cardiovascular risk factors (CVRF). There is little data on whether African American men would respond to diet and exercise interventions differently from non-Hispanic white men. We will conduct a pilot, controlled two-phase intervention study stratified by race to investigate the following objectives: 1. Compare effect of a hypocaloric, anti-inflammatory diet on changes in fat mass between African- American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy. 2. Compare effect of a hypocaloric, anti-inflammatory diet on changes in cardiovascular risk factors (body weight, lean body mass, waist-to-height ratio, blood pressure, lipids and HbA1C) and inflammatory markers (hs-CRP and cytokines) between African-American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy. 3. Compare effect of a hypocaloric, anti-inflammatory diet on changes in cancer-related fatigue and quality of life between African-American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy. We will enroll 35 African American and 35 non-Hispanic white men with prostate cancer undergoing ADT therapy. In phase 1, after baseline assessment, men will consume their habitual diet and continue their habitual activity level for 3 months. During phase 2, participants will be instructed to consume a hypocaloric (-500 kcal), anti- inflammatory diet and walk for 1 hour on 3 days per week for 3 months. At baseline, after phase 1 and 2 primary outcome (fat mass) and secondary outcomes (CVRF and inflammatory markers) and tertiary outcomes (cancer-related fatigue and quality of life) will be determined.

Key facts

Study ID

NCT06682390

Run by

University of California, Los Angeles

People needed

70

Starts

2024-03-28

Expected to finish

2027-11-29

Last updated by the study team

2025-12-15

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• >12 months on ADT
• Expected continuation of ADT for >6 months upon initiation of study procedures
• Serum testosterone <50 ng/dL
• BMI >25
• Age >18 years old
• African American and Non-Hispanic white males
• Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent

You may not qualify if…

• Life expectancy < 1 year
• Females
• Radiation or chemotherapy treatment
• History of diabetes or serious medical condition including uncontrolled hypertension, liver, kidney, and cardiovascular disease
• Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator
• Any subject who currently uses tobacco products
• Any use of >20 g of alcohol per day
• Any subject who is unable or unwilling to comply with the study protocol
• Any subject who is unable to provide consent

Where it is running

• Greater Los Angeles Division of Veterans Affairs — Los Angeles, California, United States (enrolling)
• UCLA Health 200 Medical Plaza — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.